WO2012014214A2 - Peptides dérivés de l'inhibiteur 1 de l'activateur du plasminogène (pai‑1) pour le traitement de l'hypertension - Google Patents

Peptides dérivés de l'inhibiteur 1 de l'activateur du plasminogène (pai‑1) pour le traitement de l'hypertension Download PDF

Info

Publication number
WO2012014214A2
WO2012014214A2 PCT/IL2011/000614 IL2011000614W WO2012014214A2 WO 2012014214 A2 WO2012014214 A2 WO 2012014214A2 IL 2011000614 W IL2011000614 W IL 2011000614W WO 2012014214 A2 WO2012014214 A2 WO 2012014214A2
Authority
WO
WIPO (PCT)
Prior art keywords
group
amino acid
peptide
seq
acid sequence
Prior art date
Application number
PCT/IL2011/000614
Other languages
English (en)
Other versions
WO2012014214A3 (fr
Inventor
Itschak Lamensdorf
Higazi Abd Al-Roof
Abraham Nimrod
Original Assignee
Thrombotech Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Thrombotech Ltd. filed Critical Thrombotech Ltd.
Publication of WO2012014214A2 publication Critical patent/WO2012014214A2/fr
Publication of WO2012014214A3 publication Critical patent/WO2012014214A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A47—FURNITURE; DOMESTIC ARTICLES OR APPLIANCES; COFFEE MILLS; SPICE MILLS; SUCTION CLEANERS IN GENERAL
    • A47B—TABLES; DESKS; OFFICE FURNITURE; CABINETS; DRAWERS; GENERAL DETAILS OF FURNITURE
    • A47B81/00—Cabinets or racks specially adapted for other particular purposes, e.g. for storing guns or skis
    • A47B81/007—Racks for cylindrical or barrel-like objects, e.g. casks, rolls
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B65—CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
    • B65G—TRANSPORT OR STORAGE DEVICES, e.g. CONVEYORS FOR LOADING OR TIPPING, SHOP CONVEYOR SYSTEMS OR PNEUMATIC TUBE CONVEYORS
    • B65G1/00—Storing articles, individually or in orderly arrangement, in warehouses or magazines
    • B65G1/02—Storage devices

Definitions

  • the present invention relates to peptides derived from human plasminogen activator inhibitor- 1 (PAI-1) useful for the treatment of hypertension and complications associated therewith. Particularly, the present invention relates to peptides derived from the amino acid sequence at positions 369-386 of human PAI-1 for the treatment of hypertension.
  • PAI-1 human plasminogen activator inhibitor- 1
  • Hypertension is one of the major risk factors for coronary heart disease and strokes. It can also lead to congestive heart failure, aortic dissection, and renal failure. Over half of patients with angina pectoris, sudden death, stroke, and atherothrombotic occlusion of the abdominal aorta or its branches have hypertension. Greater than 70% of people with dissecting aortic aneurysm, intracerebral hemorrhage, or rupture of the myocardial wall have high blood pressure. It is a major risk factor for atherosclerosis. Screening programs reveal that 25% of the general population is hypertensive. The prevalence of high blood pressure increases with age. However, in older age the disease is usually relatively mild compared to that in young adults where it is often more severe.
  • Non-pharmacological treatment reduction of sodium intake in food, loss of weight, physical exercise, giving up tobacco products, etc.
  • Pharmacological treatment begins with monotherapy, which allows satisfactory blood pressure control in 50-60%) of patients.
  • Changing therapeutic class as well as combination with another class of anti-hypertensive agents represent the alternative treatments in the event of resistance to the first therapy.
  • Anti-hypertensive agents include aldosterone antagonists; alpha-adrenergic receptor antagonists; potassium channel blockers; beta-adrenergic receptor antagonists; angiotensin-converting enzyme (ACE) inhibitors; angiotensin II receptor antagonists (ARBs); calcium channel antagonists; vasodilators; renin inhibitors; phosphodiesterase inhibitors; and cyclooxygenase-2 (COX-2) inhibitors.
  • ACE angiotensin-converting enzyme
  • ARBs angiotensin II receptor antagonists
  • COX-2 cyclooxygenase-2
  • WO 97/16170 discloses treatment for coronary conditions by delivering a therapeutic agent to the pericardial space.
  • a coronary condition includes hypertension and the therapeutic agent can be a polypeptide such as tPA, urokinase plasminogen activator (uPA), streptokinase and inhibitors of PAI-1.
  • WO 2007/143099 to Sobel discloses methods of inhibiting cardiac PAI-1 by administering PAI-1 antagonists.
  • cardiac PAI-1 content increases in response to age, insulin resistance, and myocardial infarction and it is believed that inhibition of cardiac PAI-1 decreases the risk for cardiovascular disease.
  • Inhibiting cardiac PAI-1 according to WO 2007/143099 could be accomplished by inhibiting the binding of cardiac PAI-1 to one of its targets, such as tPA, or by inhibiting the ability of cardiac PAI-1 to affect one of its targets.
  • PAI-1 antagonists include insulin sensitizing agents, anti-lipidemic agents and ACE inhibitors among others.
  • U.S. Patent No. 6,750,201 to Cines et al. discloses compositions comprising peptides comprising at least six amino acids derived from PAI-1, particularly disclosed is a peptide of the sequence EEIIMD, and methods of use thereof for promoting internalization and degradation of urokinase-type plasminogen activator.
  • WO 03/095476 to Higazi discloses the peptide EEIIMD and the peptide acetyl-RMAPEEIIMDRPFLYVVR-amide, compositions comprising same and uses thereof either alone or in combination with one or more fibrinolytic agents for enhancing the fibrinolytic activity of the fibrinolytic agents, for reducing the side effects due to vasoactivity caused by the fibrinolytic agents, and/or for prolonging the half lives of the fibrinolytic agents.
  • the present invention provides methods for treating hypertension comprising administering to a subject in need of such treatment an isolated peptide consisting of 18 amino acid residues corresponding to the amino acid sequence at positions 369-386 of human plasminogen activator inhibitor- 1 (PAI-1) or a fragment thereof.
  • PAI-1 human plasminogen activator inhibitor- 1
  • the present invention further provides methods for treating a hypertension-related cardiovascular disease comprising administering to a subject in need of such treatment an isolated peptide consisting of 18 amino acid residues corresponding to the amino acid sequence at positions 369-386 of human plasminogen activator inhibitor- 1 (PAI-1) or a fragment thereof, wherein the cardiovascular disease is not a thrombus-related cardiovascular disease.
  • PAI-1 human plasminogen activator inhibitor- 1
  • the present invention is based in part on the unexpected findings that an 18-mer peptide of the amino acid sequence acetyl-RMAPEEIIMDRPFLYVVR-amide (SEQ ID NO: l) corresponding to the amino acid sequence at positions 369-386 of human PAI-1 was highly effective in decreasing blood pressure in normotensive human subjects. It is disclosed that intravenous administration of the 18-mer peptide decreased the blood pressure of healthy human subjects by 20 mm Hg when measured forty minutes after peptide administration. The effect of the 18-mer peptide was reflected on both the systolic and the diastolic blood pressure.
  • the 18-mer peptide was highly effective in reducing blood pressure in spontaneously hypertensive rats. Intravenous administration of the peptide to the hypertensive rats decreased their blood pressure by about 15% of the initial blood pressure.
  • the present invention discloses uses of the 18-mer peptides or fragments thereof for reducing blood pressure in subjects having hypertension as well as in subjects having a hypertension-related cardiovascular disease.
  • the present invention excludes the uses of these peptides for the treatment of thrombus-related cardiovascular diseases.
  • the subjects to be treated according to the present invention do not undergo therapy with plasminogen activators or with proteins acting as plasminogen activators.
  • a "thrombus-related cardiovascular disease” is a disease necessitating administration of fibrinolytic agents including, but not limited to plasminogen activators.
  • the present invention is intended for treatment of hypertension not involving the concurrent need for thrombolysis.
  • the present invention provides a method for treating hypertension comprising administering to a subject in need of such treatment a pharmaceutical composition comprising a therapeutically effective amount of an isolated peptide of the amino acid sequence as set forth in SEQ ID N02:
  • Rj is selected from the group consisting of a hydrogen, acetyl, alkyl, and an amino blocking group;
  • Xi is selected from the group consisting of Asp, Glu, and Arg;
  • X 2 is selected from the group consisting of Asp and Glu; X 3 is selected from the group consisting of Asp and Glu; X4 is selected from the group consisting of Phe and Tyr; and R 2 is selected from the group consisting of a carboxyl, amide, alcohol, ester, and a carboxyl blocking group; the pharmaceutical composition further comprising a pharmaceutically acceptable carrier.
  • Xj is Glu
  • X 2 is Glu
  • X 3 is Asp
  • Ri is acetyl and R 2 is amide.
  • the peptide to be used for treating hypertension is of the amino acid sequence selected from the group consisting of SEQ ID NOs:l and 4 to 10.
  • the peptide to be used is of the amino acid sequence as set forth in SEQ ID NO: l.
  • the peptide to be used is of the amino acid sequence as set forth in SEQ ID NO:7.
  • the present invention provides a method for treating a hypertension-related cardiovascular disease comprising administering to a subject in need of such treatment a pharmaceutical composition comprising a therapeutically effective amount of an isolated peptide of the amino acid sequence as set forth in SEQ ID N02:
  • R 1 -Arg-Met-Ala-Pro-X 1 -X 2 -Ile-Ile-Met-X 3 -Arg-Pro-Phe-Leu-X 4 -Val-Val-Arg-R 2 or a fragment thereof comprising the amino acid sequence as set forth in SEQ ID NO:3,
  • Ri is selected from the group consisting of a hydrogen, acetyl, alkyl, and an amino blocking group
  • X] is selected from the group consisting of Asp, Glu, and Arg
  • X 2 is selected from the group consisting of Asp and Glu
  • X 3 is selected from the group consisting of Asp and Glu
  • X4 is selected from the group consisting of Phe and Tyr
  • R 2 is selected from the group consisting of a carboxyl, amide, alcohol, ester, and a carboxyl blocking group
  • the pharmaceutical composition further comprising a pharmaceutically acceptable carrier, and wherein the cardiovascular disease is not a thrombus-related cardiovascular disease.
  • X ⁇ is Glu
  • X 2 is Glu
  • X 3 is Asp
  • Ri is acetyl and R 2 is amide.
  • the peptide to be used for treating the cardiovascular disease is of the amino acid sequence selected from the group consisting of SEQ ID NOs: l, 4 to 10. According to a certain embodiment, the peptide to be used is of the amino acid sequence as set forth in SEQ ID NO:l . According to another embodiment, the peptide to be used is of the amino acid sequence as set forth in SEQ ID NO:7.
  • the hypertension-related cardiovascular disease is selected from the group consisting of reduced blood vessel patency, diastolic dysfunction, peripheral vascular disease, coronary artery disease, atherosclerosis, atherogenesis, angina, ischemic heart disease, myocardial infarction, and restenosis. According to some embodiments, the hypertension-related cardiovascular disease is selected from the group consisting of reduced blood patency and myocardial infarction.
  • the pharmaceutical composition is administered by intravenous, subcutaneous, intramuscular, oral, topical, transdermal, intranasal, epidural, ophthalmic, vaginal or rectal administration route.
  • the pharmaceutical composition is administered intravenously.
  • the pharmaceutical composition is formulated in a form selected from the group consisting of a solution, suspension, emulsion, tablet, gel, powder, cream, depot, and a sustained-release formulation.
  • the present invention provides an isolated peptide of the amino acid sequence as set forth in SEQ ID NO:2:
  • the present invention provides an isolated peptide of the amino acid sequence as set forth in SEQ ID NO:2:
  • FIG. 1 shows the effect of the 18-mer peptide designated THR-18 on blood pressure of hypertensive rats.
  • the present invention is based in part on the findings that an 18-mer peptide corresponding to the amino acid sequence at positions 369-386 of human PAI-1 was capable of decreasing blood pressure in animals and human subjects.
  • the present invention provides isolated peptides derived from PAI-1 for the treatment of hypertension and cardiovascular diseases associated therewith.
  • the present invention relates to the following peptides:
  • tissue-type plasminogen activator tPA
  • tPA tissue-type plasminogen activator
  • uPA urokinase
  • tPA converts plasminogen to the active protease plasmin, the latter dissolves fibrin clots by a process called fibrinolysis.
  • tPA mediates cerebrovasodilation which leads to intracerebral hemorrhage.
  • the present invention discloses for the first time that the 18-mer peptide of SEQ ID NO:l or analogs or fragments thereof when administered in the absence of fibrinolytic agents such as tPA or uPA, can exert significant antihypertensive effect.
  • these peptides as well as their analogs and fragments are useful for treating hypertension and cardiovascular diseases attributed to hypertension.
  • the present invention provides a peptide having the amino acid sequence of general formula I:
  • the present invention provides uses of 6 to 18-mer peptides comprising in a preferred embodiment the sequence EEIIMD, for the treatment of hypertension or cardiovascular diseases attributed to hypertension, with the proviso that the treatment excludes co-treatment with plasminogen activators or with proteins acting as plasminogen activators.
  • the peptide is an 18- mer peptide of the amino acid sequence Ac-RMAPEEIIMDRPFLYVVR-amide as set forth in SEQ ID NO:l, or a fragment thereof comprising the sequence EEIIMD.
  • the peptide is of the amino acid sequence as set forth in SEQ ID NO: 1.
  • peptide designates a linear series of amino acid residues connected one to the other by peptide bonds.
  • amino acid residues are represented throughout the specification and claims by one-letter or three-letter codes according to IUPAC conventions.
  • amino acid or “amino acid residue” is understood to include the 20 naturally occurring amino acids.
  • the peptides of the present invention consist of 6 to 18 amino acid residues.
  • the peptides of the present invention can be isolated by any protein purification method known in the art.
  • PAI-1 can be subjected to one or more proteolytic enzymes to yield a mixture of peptides, which can further be purified by any protein purification method known in the art to obtain the isolated peptides.
  • PAI-1 can be cleaved by chemical agents such as, for example, CNBr to yield a mixture of peptides that can be further purified to obtain isolated peptides.
  • the peptides of the present invention can also be prepared by methods well known in the art including chemical synthesis or recombinant DNA technology.
  • a preferred method of synthesizing the peptides of the present invention involves solid- phase peptide synthesis utilizing a solid support as described by Merrifield (see J. Am. Chem. Soc, 85:2149, 1964). Large-scale peptide synthesis is described, for example, by Andersson et al. (Biopolymers 55(3): 227-50, 2000).
  • solid phase peptide synthesis methods include the BOC method, which utilizes tert-butyloxcarbonyl as the a- amino protecting group, and the FMOC method, which utilizes 9- fluorenylmethyloxcarbonyl to protect the a-amino of the amino acid residues, both methods are well-known by those of skill in the art.
  • the peptides of the present invention can be synthesized by standard solution synthesis methods (see, for example, Bodanszky, M., Principles of Peptide Synthesis, Springer- Verlag, 1984).
  • the peptides useful for practicing the present invention need not consist of an amino acid sequence identical to RMAPEEIIMDRPFLYVVR set forth in SEQ ID NO:4 or RMAPEEIIMDRPFLFVVR set forth in SEQ ID NO:8 so long as the peptide analogs are capable of treating and/or preventing hypertension or a cardiovascular disease attributed to hypertension.
  • the term "analog” includes any peptide comprising altered sequence by amino acid substitutions, deletions, or chemical modifications of the peptides listed herein above and which displays anti-hypertensive activity. By using "amino acid substitutions", it is meant that functionally equivalent amino acid residues are substituted for residues within the sequence resulting in a silent change.
  • one or more amino acid residues within the sequence can be substituted by another amino acid of a similar polarity, which acts as a functional equivalent, resulting in a silent alteration.
  • Substitutes for an amino acid within the sequence may be selected from other members of the class to which the amino acid belongs.
  • the non-polar (hydrophobic) amino acids include alanine, leucine, isoleucine, valine, proline, phenylalanine, tryptophan and methionine.
  • the polar neutral amino acids include glycine, serine, threonine, cysteine, tyrosine, asparagine, and glutamine.
  • the positively charged (basic) amino acids include arginine, lysine and histidine.
  • the negatively charged (acidic) amino acids include aspartic acid and glutamic acid. Such substitutions are known as conservative substitutions. Additionally, a non-conservative substitution may be made so long as the anti- hypertension activity of the peptide is maintained. It will be appreciated that the present invention encompasses peptide analogs, wherein one or more amino acids are substituted by another amino acid to produce a peptide analog having increased stability or longer half-life as compared to the peptides listed herein above.
  • amino acid residues of the peptide sequences set forth herein above are all in the "L” isomeric form
  • residues in the "D” isomeric form can substitute any L- amino acid residue so long as the peptide analog retains anti-hypertension activity.
  • Production of a retro-inverso D-amino acid peptide analog where the peptide is made with the same amino acids as disclosed, but at least one amino acid, and perhaps all amino acids are D-amino acids is well known in the art.
  • the result is an analog having the same structural groups being at the same positions as in the L-amino acid form of the peptide.
  • the peptide analog is more stable to proteolytic degradation and is therefore useful in many of the applications recited herein.
  • the present invention further encompasses peptide derivatives of the peptides listed herein above.
  • derivative refers to a peptide having an amino acid sequence that comprises the amino acid sequence of the peptide of the invention, in which one or more of the amino acid residues is subjected to chemical derivatizations by a reaction of side chains or functional groups, where such derivatizations do not destroy the anti-hypertension activity of the peptide derivative.
  • Chemical derivatization of amino acid residues include, but are not limited to, acetylation, amidation, glycosylation, oxidation, reduction, myristylation, sulfation, acylation, ADP-ribosylation, cyclization, disulfide bond formation, hydroxylation, iodination, and methylation.
  • Blocking groups are well known to those of skill in the art as are methods of coupling such groups to the appropriate residue(s) of the peptides of the present invention (see, e.g., Greene et al., (1991) Protective Groups in Organic Synthesis, 2nd ed., John Wiley & Sons, Inc. Somerset, N.J.).
  • the terminal amino acids of the peptides of the invention are blocked with a protecting or blocking group.
  • blocking groups include, but are not limited to, acetyl, alkyl and amide groups with acetyl and alkyl groups being particularly preferred for N-terminal protection and amide groups being preferred for carboxyl terminal protection.
  • an acetyl group is used to protect the amino terminus and an amide group is used to protect the carboxyl terminus.
  • the protecting groups can include alkyl chains as in fatty acids, propeonyl, formyl, or others.
  • Particularly preferred carboxyl blocking groups include amides, esters, and ether-forming blocking groups.
  • blocking groups include, but are not limited to Fmoc, t-butoxycarbonyl (t- BOC), 9-fluoreneacetyl group, 1-fluorenecarboxylic group, 9-florenecarboxylic group, 9- fluorenone-l-carboxylic group, benzyloxycarbonyl, Xanthyl (Xan), Trityl (Trt), 4- methyltrityl (Mtt), 4-methoxytrityl (Mmt), 4-methoxy-2,3,6-trimethylbenzenesulphonyl (Mtr), Mesitylene-2-sulphonyl (Mts), 4,4-dimethoxybenzhydryl (Mbh), Tosyl (Tos), 2,2,5,7,8-pentamethyl chroman-6-sulphonyl (Pmc), 4-methylbenzyl (MeBzl), 4- methoxybenzyl (MeOBzl), Benzyloxy (BzlO
  • peptides which contain one or more naturally occurring amino acid derivatives of the twenty standard amino acid residues.
  • 4-hydroxyproline may be substituted for proline
  • 5 -hydroxy lysine may be substituted for lysine
  • 3-methylhistidine may be substituted for histidine
  • homoserine may be substituted for serine
  • ornithine may be substituted for lysine.
  • the peptides may also contain non-natural amino acids.
  • non-natural amino acids are norleucine, ornithine, citrulline, diaminobutyric acid, homoserine, isopropyl Lys, 3-(2'-naphtyl)-Ala, nicotinyl Lys, amino isobutyric acid, and 3-(3'-pyridyl-Ala).
  • the peptides may also contain non-protein side chains or one or more non-amino acid monomers (e.g., fatty acids, complex carbohydrates, and the like).
  • the present invention includes conjugates of the peptides of the invention.
  • conjugates are meant to define a peptide of the present invention coupled to or conjugated with another protein or polypeptide. Such conjugates may have advantages over the peptides themselves.
  • conjugates can be made by protein synthesis, e. g., by use of a peptide synthesizer, or by ligating the appropriate nucleic acid sequences encoding the desired amino acid sequences to each other by methods known in the art, in the proper coding frame, and expressing the chimeric protein by methods commonly known in the art.
  • a peptide of the present invention may also be conjugated to itself or aggregated in such a way as to produce a large complex containing the peptide.
  • Such large complexes may be advantageous because they may have new biological properties such as longer half-life in circulation or greater activity.
  • compositions and administration routes are provided.
  • the present invention provides methods for treating or preventing hypertension or a cardiovascular disease due to hypertension comprising administering to a subject having hypertension or the hypertension-related cardiovascular disease a pharmaceutical composition comprising a therapeutically effective amount of a peptide of the invention and a pharmaceutically acceptable carrier.
  • the term "pharmaceutical composition” refers to a preparation of one or more of the peptides described herein with other chemical components such as pharmaceutically acceptable carriers and excipients.
  • the purpose of the pharmaceutical composition is to facilitate administration of the one or more peptides to an organism.
  • pharmaceutically acceptable means approved by a regulatory agency of the Federal or a state government or listed in the U.S. Pharmacopeia or other generally recognized pharmacopeia for use in animals, and more particularly in humans.
  • compositions of the present invention can be formulated as pharmaceutically acceptable salts of the peptides of the present invention.
  • pharmaceutically acceptable salts refers to salts prepared from pharmaceutically acceptable non-toxic bases or acids including inorganic or organic bases and inorganic or organic acids. Salts derived from inorganic bases include aluminum, ammonium, calcium, copper, ferric, ferrous, lithium, magnesium, manganous, potassium, sodium, zinc, and the like. Particularly preferred are the ammonium, calcium, magnesium, potassium, and sodium salts.
  • Salts derived from pharmaceutically acceptable organic non-toxic bases include salts of primary, secondary, and tertiary amines, substituted amines including naturally occurring substituted amines, cyclic amines, and basic ion exchange resins, such as arginine, betaine, caffeine, choline, ⁇ , ⁇ '- dibenzylethylenediamine, diethylamine, 2-diethylaminoethanol, 2-dimethylaminoethanol, ethanolamine, ethylenediamine, N-ethyl-morpholine, N-ethylpiperidine, glucamine, glucosamine, histidine, hydrabamine, isopropylamine, lysine, methylglucamine, morpholine, piperazine, piperidine, polyamine resins, procaine, purines, theobromine, triethylamine, trimethylamine, tripropylamine, tromethamine, and the like.
  • basic ion exchange resins such as
  • salts may be prepared from pharmaceutically acceptable non-toxic acids, including inorganic and organic acids.
  • acids include acetic, trifluoroacetic, benzenesulfonic, benzoic, camphorsulfonic, citric, ethanesulfonic, fumaric, gluconic, glutamic, hydrobromic, hydrochloric, isethionic, lactic, maleic, malic, mandelic, methanesulfonic, mucic, nitric, pamoic, pantothenic, phosphoric, succinic, sulfuric, tartaric, p-toluenesulfonic acid, and the like.
  • carrier refers to a diluent or vehicle that does not cause significant irritation to an organism and does not abrogate the biological activity and properties of the administered compound.
  • An adjuvant is included under these phrases.
  • Such pharmaceutical carriers can be sterile liquids, such as water and oils, including those of petroleum, animal, vegetable or synthetic origin, such as peanut oil, soybean oil, mineral oil, sesame oil and the like, polyethylene glycols, glycerin, propylene glycol or other synthetic solvents. Water is a preferred carrier when the pharmaceutical composition is administered intravenously. Saline solutions and aqueous dextrose and glycerol solutions can also be employed as liquid carriers, particularly for injectable solutions.
  • compositions of the invention can further comprise an excipient.
  • excipient refers to an inert substance added to a pharmaceutical composition to further facilitate administration of an active ingredient.
  • suitable pharmaceutical excipients include mannitol, starch, glucose, lactose, sucrose, trehalose, gelatin, silica gel, sodium stearate, glycerol monostearate, talc, sodium chloride, dried skim milk, propylene glycol, ethanol and the like.
  • composition can also contain minor amounts of wetting or emulsifying agents; pH buffering agents such as acetates, citrates or phosphates; antibacterial agents such as benzyl alcohol or methyl parabens; antioxidants such as ascorbic acid or sodium bisulfite; chelating agents such as ethyl enediaminetetraacetic acid; and agents for the adjustment of tonicity such as sodium chloride or dextrose.
  • pH buffering agents such as acetates, citrates or phosphates
  • antibacterial agents such as benzyl alcohol or methyl parabens
  • antioxidants such as ascorbic acid or sodium bisulfite
  • chelating agents such as ethyl enediaminetetraacetic acid
  • agents for the adjustment of tonicity such as sodium chloride or dextrose.
  • compositions of the present invention can be manufactured by processes well known in the art, e.g., by means of conventional mixing, dissolving, granulating, dragee-making, levigating, emulsifying, encapsulating, entrapping, or lyophilizing processes.
  • compositions which contain peptides as active ingredients are prepared as injectable, either as liquid solutions or suspensions, however, solid forms, which can be suspended or solubilized prior to injection, can also be prepared.
  • the compositions can also take the form of emulsions, tablets, gels, slurries, powders, creams, depots, sustained-release formulations and the like.
  • Methods of introduction of a pharmaceutical composition comprising a peptide of the invention include, but are not limited to, intravenous, subcutaneous, intramuscular, intraperitoneal, oral, topical, transdermal, intranasal, epidural, ophthalmic, vaginal and rectal routes.
  • the pharmaceutical compositions can be administered by any convenient route, for example by infusion or bolus injection, by absorption through epithelial linings (e.g., oral mucosa, rectal and intestinal mucosa, etc.), and may be administered together with other therapeutically active agents.
  • the administration may be localized, or may be systemic. Pulmonary administration can also be employed, e.g., by use of an inhaler or neubilizer.
  • the pharmaceutical composition is administered by bolus injection.
  • compositions for use in accordance with the present invention may be formulated in conventional manner using one or more physiologically acceptable carriers further comprising excipients which facilitate processing of the active ingredients into preparations that can be used pharmaceutically. Proper formulation is dependent upon the route of administration chosen.
  • the active ingredients of the pharmaceutical composition may be formulated in aqueous solutions, preferably in physiologically compatible buffers such as Hank's solution, Ringer's solution, or physiological salt buffer.
  • physiologically compatible buffers such as Hank's solution, Ringer's solution, or physiological salt buffer.
  • penetrants appropriate to the barrier to be permeated are used in the formulation. Such penetrants are generally known in the art.
  • the pharmaceutical composition can be formulated readily by combining the active ingredients with pharmaceutically acceptable carriers well known in the art.
  • Such carriers enable the pharmaceutical composition to be formulated as tablets, dragees, liquids, gels, slurries, suspensions, and the like, for oral ingestion by a patient.
  • Pharmacological preparations for oral use can be made using a solid excipient, optionally grinding the resulting mixture, and processing the mixture of granules, after adding suitable excipients as desired, to obtain tablets or dragee cores.
  • Suitable excipients are, in particular, fillers such as sugars, including lactose, sucrose, mannitol, or sorbitol; cellulose preparations such as, for example, maize starch, wheat starch, rice starch, potato starch, gelatin, gum tragacanth, methyl cellulose, hydroxypropylmethyl-cellulose, and sodium carbomethylcellulose; and/or physiologically acceptable polymers such as polyvinylpyrrolidone (PVP).
  • disintegrating agents such as cross-linked polyvinyl pyrrolidone, agar, or alginic acid or a salt thereof, such as sodium alginate, may be added.
  • Dragee cores are provided with suitable coatings.
  • suitable coatings For this purpose, concentrated sugar solutions may be used which may optionally contain gum arabic, talc, polyvinyl pyrrolidone, carbopol gel, polyethylene glycol, titanium dioxide, lacquer solutions, and suitable organic solvents or solvent mixtures.
  • Dyestuffs or pigments may be added to the tablets or dragee coatings for identification or to characterize different combinations of active compound doses.
  • compositions that can be used orally include push-fit capsules made of gelatin, as well as soft, sealed capsules made of gelatin and a plasticizer, such as glycerol or sorbitol.
  • the push-fit capsules may contain the active ingredients in admixture with filler such as lactose, binders such as starches, lubricants such as talc or magnesium stearate, and, optionally, stabilizers.
  • the active ingredients may be dissolved or suspended in suitable liquids, such as fatty oils, liquid paraffin, or liquid polyethylene glycols.
  • stabilizers may be added.
  • compositions may take the form of tablets or lozenges formulated in conventional manner.
  • the active ingredients for use according to the present invention are conveniently delivered in the form of an aerosol spray presentation from a pressurized pack or a neubilizer with the use of a suitable propellant, e.g., dichlorodifluoromethane, trichlorofluoromethane, dichloro-tetrafluoroethane, or carbon dioxide.
  • a suitable propellant e.g., dichlorodifluoromethane, trichlorofluoromethane, dichloro-tetrafluoroethane, or carbon dioxide.
  • the dosage may be determined by providing a valve to deliver a metered amount.
  • Capsules and cartridges of, for example, gelatin for use in a dispenser may be formulated containing a powder mix of the compound and a suitable powder base, such as lactose or starch.
  • compositions described herein may be formulated for parenteral administration, e.g., by bolus injection or continuous infusion.
  • Formulations for injection may be presented in unit dosage form, e.g., in ampoules or in multidose containers with, optionally, an added preservative.
  • the compositions may be suspensions, solutions, or emulsions in oily or aqueous vehicles, and may contain formulatory agents such as suspending, stabilizing, and/or dispersing agents.
  • compositions for parenteral administration include aqueous solutions of the active preparation in water-soluble form. Additionally, suspensions of the active ingredients may be prepared as appropriate oily or water-based injection suspensions. Suitable lipophilic solvents or vehicles include fatty oils such as sesame oil, or synthetic fatty acid esters such as ethyl oleate, triglycerides, or liposomes. Aqueous injection suspensions may contain substances that increase the viscosity of the suspension, such as sodium carboxymethyl cellulose, sorbitol, or dextran. Optionally, the suspension may also contain suitable stabilizers or agents that increase the solubility of the active ingredients, to allow for the preparation of highly concentrated solutions.
  • the active ingredient may be in powder form for constitution with a suitable vehicle, e.g., a sterile, pyrogen-free, water-based solution, before use.
  • a suitable vehicle e.g., a sterile, pyrogen-free, water-based solution
  • compositions of the present invention may also be formulated in rectal compositions such as suppositories or retention enemas, using, for example, traditional binders and carriers such as triglycerides, microcrystalline cellulose, gum tragacanth or gelatin.
  • the pharmaceutical composition may be in the form of tablets or capsules, which can contain any of the following ingredients, or compounds of a similar nature: a binder such as microcrystalline cellulose, gum tragacanth or gelatin; an excipient such as starch or lactose; a disintegrating agent such as alginic acid, Primogel, or corn starch; a lubricant such as magnesium stearate or Sterotes; or a glidant such as colloidal silicon dioxide.
  • a binder such as microcrystalline cellulose, gum tragacanth or gelatin
  • an excipient such as starch or lactose
  • a disintegrating agent such as alginic acid, Primogel, or corn starch
  • a lubricant such as magnesium stearate or Sterotes
  • a glidant such as colloidal silicon dioxide.
  • dosage unit form can contain, in addition to the materials of the above type, a liquid carrier such as fatty oil.
  • dosage unit forms can contain other materials which modify the
  • a peptide of the invention can be delivered in a controlled release system.
  • the peptide can be administered in combination with a biodegradable, biocompatible polymeric implant, which releases the peptide over a controlled period of time at a selected site.
  • a biodegradable, biocompatible polymeric implant which releases the peptide over a controlled period of time at a selected site.
  • preferred polymeric materials include polyanhydrides, polyorthoesters, polyglycolic acid, polylactic acid, polyethylene vinyl acetate, copolymers and blends thereof (See, Medical applications of controlled release, Langer and Wise (eds.), 1974, CRC Pres., Boca Raton, Fla.).
  • a controlled release system can be placed in proximity of the therapeutic target, thus requiring only a fraction of a systemic dose.
  • the present invention provides peptides for the treatment of hypertension.
  • the present invention further provides peptides for the treatment of cardiovascular diseases attributed to hypertension with the proviso that the treatment of the cardiovascular disease excludes a combination therapy with plasminogen activators or with proteins acting as plasminogen activators.
  • treatment includes both treatment and/or prophylactic use of the pharmaceutical compositions comprising the peptides of the invention.
  • prophylactic use of the pharmaceutical compositions comprises administering to a subject in heed of such treatment a therapeutically effective amount of the pharmaceutical composition disclosed herein above to prevent the onset of hypertension or a cardiovascular disease attributed to hypertension; and to prevent the progression of hypertension or the cardiovascular disease, wherein the subject having or at risk of having the cardiovascular disease is not co-treated with plasminogen activators or with proteins acting as plasminogen activators.
  • a "therapeutically effective amount” means an amount of a peptide effective to prevent, alleviate, or ameliorate hypertension or symptoms of a cardiovascular disease attributed to hypertension in the subject being treated.
  • hypertension refers to chronic hypertension, systolic hypertension, diabetic hypertension, pulmonary hypertension, acute severe hypertension, ocular hypertension and any combination thereof. According to a certain embodiment, hypertension is acute severe hypertension.
  • hypertension-related cardiovascular disease refers to any cardiovascular disease or disorder known in the art which is attributed to hypertension, including, but not limited to, diastolic dysfunction, reduced blood vessel patency, peripheral vascular disease (including vascular ischemia), coronary artery disease, myocardial infarction, atherosclerosis, atherogenesis, angina (including chronic, stable, unstable and variant (Prinzmetal) angina pectoris), myocardial ischemia, and restenosis. It is to be understood that thrombus-related cardiovascular diseases are excluded from the present invention.
  • thrombus-related cardiovascular disease refers to a cardiovascular disease which is attributed to thrombi formation and which disease requires administering of fibrinolytic agents such as, for example, plasminogen activators in order to treat the disease.
  • plasminogen activator refers to any protein capable of activating plasminogen and as such to be useful in fibrinolytic therapy. Without being bound by any mechanism of action, activation of plasminogen to plasmin can take place by enzymatic cleavage (e.g., by tissue-type plasminogen activator or uPA) or by a conformational change.
  • Plasminogen activators include, but are not limited to, urokinase (uPA), tissue- type plasminogen activator (tPA), streptokinase, single chain urokinase (scuPA), two chain uPA (tcuPA), rt-PA,reteplase, reteplase, lanoteplase, TNK-rt-PA, anisoylated plasminogen streptokinase complex, anistreplase, and derivatives thereof (see, for example, U.S. Patent No. 7,271,143 indicated by reference as if fully set forth herein).
  • Heart failure includes, but is not limited to congestive heart failure, compensated heart failure, decompensated heart failure, and the like.
  • the subject is a mammal.
  • the mammal is a human.
  • the precise amount of the peptide to be administered to a particular subject, preferably a mammal, more preferably a human being, in the method of treatment of the present invention will depend on a number of factors, for example the specific peptide administered; its mode of administration; the particular clinical condition being treated and/or its severity; and/or the age, body mass and/or past clinical history of the patient to be treated, and always lies within the sound discretion of the person administering and/or supervising the treatment, for example a medical practitioner such as nurse and/or physician.
  • a suitable daily dose of the peptide for administration to a mammal is generally from about 0.01 mg/day per kg of the mammal's body mass to about 80 mg/kg/day, more usually 0.2-40 mg/kg/day given in a single dose and/or in divided doses at one or more times during the day.
  • the pharmaceutical composition can contain from about 0.1% to about 99% by weight of the peptide and is generally prepared in unit dose form, a unit dose of a peptide generally being from about 0.1 mg to about 500 mg.
  • Dosage amount and administration intervals may be adjusted individually to provide sufficient plasma levels of the peptide to induce an anti-hypertensive effect.
  • dosing can be of a single or a plurality of administrations, with course of treatment lasting from several days to several weeks, or until cure is effected or diminution of the disease state is achieved.
  • the peptides of the present invention can be administered alone or in conjunction with other therapeutic agents.
  • Therapeutic agent includes any therapeutic agent that can be used to treat or prevent the diseases described herein.
  • Therapeutic agents include, for example, aldosterone antagonists, alpha-adrenergic receptor antagonists, angiotensin II antagonists, angiotensin-converting enzyme (ACE) inhibitors, anti-hyperlipidemic compounds, vasodilator compounds, ⁇ -adrenergic antagonists, calcium channel blockers, diuretics, endothelin antagonists, phosphodiesterase inhibitors, potassium channel blockers, proton pump inhibitors, renin inhibitors, selective cyclooxygenase-2 (COX-2) inhibitors, and the like.
  • ACE angiotensin-converting enzyme
  • COX-2 selective cyclooxygenase-2
  • a cardiovascular safety study was conducted in telemetered beagle dogs. The study was designed to examine the effects of the 18-mer peptide of SEQ ID NO:l designated THR-18 on the blood pressure (systolic, diastolic, mean), heart rate, ECG and clinical signs after escalating single intravenous slow bolus doses of 0 (vehicle), 5, 10 and 20 mg/kg (3 males and 3 females/dose group).
  • Treatment with THR-18 at a low dose of (5 mg/kg) resulted in a slight but not statistically significant decrease of the blood pressure parameters in females (15% in systemic blood pressure), 30 min after the treatment.
  • the decrease was slightly stronger in the females (35%-49% in SP) than in the males (25%- 42% in SP).
  • the blood pressure parameters returned to the baseline in both genders.
  • Subjects (6 subjects/group) were exposed to escalating doses of 0.25, 0.5, 0.75 and 1 mg/kg of THR-18, administered by intravenous infusion during 15 min. No significant effects were seen in the 0.25 and 0.5 mg/kg treated groups. However, a moderate lowering of blood pressure was seen in two subjects in the 0.75 mg/kg group, and a further drop of about 20 mm Hg was evident in 5 out of the 6 subjects in the 1 mg/kg group. The effect in this group was maximal at 40 min post infusion.
  • the rats were anesthetized by subcutaneous administration of ketamine:xylazine during the surgical procedure to expose the right jugular vein, left carotid artery and trachea.
  • a heparinized polyethylene cannula was inserted into the carotid artery for monitoring the pulsatile blood pressure (BP) via a pressure transducer connected to a Biopac system TSD 104 A.
  • BP pulsatile blood pressure
  • the 18-mer peptide of SEQ ID NO: l (designated THR-18) was prepared as a trifluoroacetic acid salt and administered to the rats at a dose of 2.5 mg/kg or 10 mg/kg in a volume of 10 ml/kg (6 rats in each group).
  • the carrier was 5% mannitol in water for injection.
  • a control group received the carrier only.
  • the peptide or carrier were administered by a bolus intravenous administration of 10% of the dose volume during two minutes and the rest of the dose was administered by infusion (dosing) during one hour.
  • the rats weight on average 300 gr.
  • the results of the blood pressure as monitored during the bolus injection, infusion and thereafter are presented in FIG. 1.
  • the initial blood pressure (BP) of the rats was 100 ⁇ 5 mmHg (Mean ⁇ S.D.).
  • Administration of the carrier or 2.5 mg/kg THR-18 caused a rapid increase of 5-10% of the initial blood pressure (FIG. 1). This small increase was not statistically significant (p>0.05; according to paired t-test), and it may be related to the effect of anesthesia on the SHR rats.
  • the blood pressure of the rats receiving the high dose of THR-18 (10 mg/kg) did not increase after bolus injection and infusion, and one hour later, a decrease in the BP of

Landscapes

  • Engineering & Computer Science (AREA)
  • Mechanical Engineering (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Tyre Moulding (AREA)

Abstract

La présente invention concerne des peptides dérivés de l'inhibiteur 1 de l'activateur du plasminogène (PAI-1) humain pour le traitement de l'hypertension et des complications qui y sont associées. Particulièrement, la présente invention concerne des peptides dérivés de la séquence d'acides aminés aux positions 369-386 du PAI-1 humain pour le traitement de l'hypertension.
PCT/IL2011/000614 2010-07-28 2011-07-28 Peptides dérivés de l'inhibiteur 1 de l'activateur du plasminogène (pai‑1) pour le traitement de l'hypertension WO2012014214A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US36826810P 2010-07-28 2010-07-28
US61/368,268 2010-07-28

Publications (2)

Publication Number Publication Date
WO2012014214A2 true WO2012014214A2 (fr) 2012-02-02
WO2012014214A3 WO2012014214A3 (fr) 2012-07-19

Family

ID=45526910

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IL2011/000614 WO2012014214A2 (fr) 2010-07-28 2011-07-28 Peptides dérivés de l'inhibiteur 1 de l'activateur du plasminogène (pai‑1) pour le traitement de l'hypertension

Country Status (2)

Country Link
US (1) US20120027558A1 (fr)
WO (1) WO2012014214A2 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4112069A4 (fr) * 2020-02-26 2023-09-27 Talengen International Limited Procédé et médicament pour la prévention et le traitement d'un problème de pression artérielle anormale

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104723307A (zh) * 2013-12-19 2015-06-24 肖作鹏 一种汽车轮胎存放架
USD740059S1 (en) 2014-04-09 2015-10-06 Edward R. Gaffey Vehicle tire storage container
EP2947030A1 (fr) * 2014-05-23 2015-11-25 Pesmel Group Oy Transtockeur comprenant deux plateformes de chargement et méthode utilisant un tel transélévateur dans un entrepôt
US9457703B2 (en) * 2015-02-17 2016-10-04 William N. Moore Mobile tire storage
US9710783B1 (en) * 2016-03-31 2017-07-18 Thomas J. Allen System for tire storage, retrieval, and inventory management
US9466047B1 (en) * 2016-03-31 2016-10-11 Thomas J. Allen System for tire storage, retrieval, and inventory management
BR112019012833B1 (pt) * 2016-12-23 2022-07-26 Embraer S.A. Dispositivo de armazenamento de pneu
WO2019088943A1 (fr) 2017-11-01 2019-05-09 Bozkurt Ugur Modèle d'optimisation et d'automatisation de stockage de pneus d'automobiles
US10980342B2 (en) * 2018-06-19 2021-04-20 Glenn Ehrgott Tire rack securing system
WO2021207341A1 (fr) * 2020-04-08 2021-10-14 Koetter-Rax, Llc Système de stockage modulaire pour fûts
CN117842576B (zh) * 2024-03-07 2024-05-03 雄鹰轮胎(青州)有限公司 轮胎胎胚立体存储设备

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030125233A1 (en) * 2000-06-27 2003-07-03 Peter Carmeliet Use of urokinase inhibitors for the treatment and/or prevention of pulmonary hypertension and/or cardiac remodelling
WO2009013753A1 (fr) * 2007-07-24 2009-01-29 Thrombotech Ltd. Peptides issus de l'inhibiteur 1 de l'activateur du plasminogène et leurs utilisations

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4941578A (en) * 1988-08-05 1990-07-17 Devening Charles K High density storage system
DE4037210C2 (de) * 1990-11-22 1994-11-17 Sp Reifenwerke Gmbh Palette
US5680942A (en) * 1995-05-18 1997-10-28 Metal Masters Foodservice Equipment Co., Inc. Overhead track high density storage system with center and side guide rollers and caster lock alignment clip
US6290074B1 (en) * 1999-05-24 2001-09-18 Rtc Industries, Inc. Storage and display rack and shelf therefor
US7143474B2 (en) * 2003-06-17 2006-12-05 Metro Industries, Inc. Compact, modular storage system
US7413091B2 (en) * 2004-04-15 2008-08-19 Big O Tires, Inc. Rolling storage rack system
WO2006028644A2 (fr) * 2004-08-11 2006-03-16 American Express Travel Related Services Company, Inc. Support pour pneumatiques, systeme et procede de chargement et de dechargement
CN101535151B (zh) * 2006-11-16 2012-07-04 平田机工株式会社 存放系统和存放方法
US8020714B2 (en) * 2007-10-31 2011-09-20 Presence From Innovation, Llc Product merchandising system for walk-in display coolers and the like

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030125233A1 (en) * 2000-06-27 2003-07-03 Peter Carmeliet Use of urokinase inhibitors for the treatment and/or prevention of pulmonary hypertension and/or cardiac remodelling
WO2009013753A1 (fr) * 2007-07-24 2009-01-29 Thrombotech Ltd. Peptides issus de l'inhibiteur 1 de l'activateur du plasminogène et leurs utilisations

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4112069A4 (fr) * 2020-02-26 2023-09-27 Talengen International Limited Procédé et médicament pour la prévention et le traitement d'un problème de pression artérielle anormale

Also Published As

Publication number Publication date
US20120027558A1 (en) 2012-02-02
WO2012014214A3 (fr) 2012-07-19

Similar Documents

Publication Publication Date Title
WO2012014214A2 (fr) Peptides dérivés de l'inhibiteur 1 de l'activateur du plasminogène (pai‑1) pour le traitement de l'hypertension
JP2755351B2 (ja) 抗―凝集ペプチド
EP0276014B1 (fr) Peptides anticoagulants
EP3340974B1 (fr) Peptides pour le traitement de l'infarctus du myocarde
CA2795168A1 (fr) Inhibiteurs de facteur xii pour traiter une maladie pulmonaire interstitielle
EP0725797B1 (fr) Inhibiteurs bivalents de thrombine
EP2173371B1 (fr) Peptides issus de l'inhibiteur 1 de l'activateur du plasminogène et leurs utilisations
KR0131378B1 (ko) 항응고성 펩티드 알코올
CN102482323A (zh) 新型肽及其应用
HU207103B (en) Process for producing anticoagulant peptides and pharmaceutical compositions comprising same
US6015790A (en) Methods and compositions for treating rheumatoid arthritis
JP2002517197A (ja) プロテアーゼインヒビターペプチド
CA2086243C (fr) Peptides anticoagulants
EP0372503A2 (fr) Peptides anticoagulants
WO2005095443A1 (fr) Système d'administration médicamenteuse utilisant un peptide modifié
WO2012104462A1 (fr) Heptapeptides et leur utilisation pour la régulation de l'hypertension
WO2011086557A1 (fr) Peptides destinés au traitement de maladies respiratoires
US4971953A (en) Anticoagulant peptide alcohols
US5789540A (en) Anticoagulant peptides
WO2022156189A1 (fr) Utilisation d'un composé polypeptidique dans la prévention ou le traitement d'une maladie intestinale inflammatoire et d'une fibrose intestinale associée
US20140256645A1 (en) Extract and peptides derived from oryza sativa japonica group and uses thereof
JP2003342296A (ja) メグシン活性阻害因子
WO2000047606A1 (fr) Peptides inhibant la migration des cellules endotheliales vasculaires
WO1999019356A1 (fr) Inhibiteur de thrombine trivalent
KR20130032787A (ko) 심혈관 질환 예방 및 치료용 펩타이드 및 이의 용도

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11811939

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 11811939

Country of ref document: EP

Kind code of ref document: A2